aTyr Pharma (NASDAQ:ATYR) Stock Gets Downgrade from Wall Street Zen

aTyr Pharma (NASDAQ:ATYR – Get Free Report) was downgraded by Wall Street Zen from a “hold” rating to a “strong sell” rating in a research note issued on Saturday, Wall Street Zen reports.

Several other analysts also recently weighed in on the stock. Weiss Ratings downgraded shares of aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. Royal Bank Of Canada cut their target price on aTyr Pharma to $6.00 and set a “sector perform” rating on the stock in a research report on Friday, November 6th. Freedom Broker cut aTyr Pharma from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 6th. Finally, Wells Fargo & Company raised their price target on aTyr Pharma from $1.00 to $4.00 and gave the stock an “equal weight” rating in a research report on Friday, November 6th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $5.00.

Check Out Our Latest Research Report on aTyr Pharma

aTyr Pharma Price Performance

Shares of ATYR opened at $6.11 on Friday. aTyr Pharma has a 1-year low of $4.07 and a 1-year high of $44.40. The stock has a market cap of $15.58 million, a PE ratio of -0.28 and a beta of 1.05. The firm has a 50-day simple moving average of $10.33 and a two-hundred day simple moving average of $23.04.

aTyr Pharma (NASDAQ:ATYR – Get Free Report) last released its quarterly earnings results on Friday, November 6th. The company reported ($7.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($4.00) by ($3.43). As a group, sell-side analysts expect that aTyr Pharma will post -22.96 earnings per share for the current fiscal year.

Institutional Trading of aTyr Pharma

An institutional investor recently bought a new position in aTyr Pharma stock. Renaissance Technologies LLC purchased a new position in shares of aTyr Pharma, Inc. (NASDAQ:ATYR – Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 40,522 shares of the company’s stock, valued at approximately $32,000. 61.72% of the stock is owned by institutional investors.

About aTyr Pharma

(Get Free Report)

aTyr Pharma is a clinical-stage biotechnology company focused on developing medicines based on the extracellular biology of tRNA synthetases, a family of proteins involved in cellular processes. The company is headquartered in San Diego, California. Its lead drug candidate, efzofitimod, is an immunomodulator being studied for pulmonary sarcoidosis and other interstitial lung diseases. The candidate is designed to act through neuropilin-2, a receptor involved in immune regulation. aTyr’s research programs draw on its work in tRNA synthetase biology, with the broader goal of developing treatments for inflammatory and fibrotic conditions.

Further Reading

Analyst Recommendations for aTyr Pharma (NASDAQ:ATYR)

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.